Stockreport

Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media

NOVUS THERAPEUTICS  (NVUS) 
US:NASDAQ Investor Relations: ir.novustherapeutics.com/news-releases
PDF IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorde [Read more]